Access to medicines in South Africa is shaped by a complex intersection of regulatory frameworks, procurement mechanisms, pricing structures, supply chain logistics, and human resource capacity. While recent reforms have targeted specific challenges, such as regulatory backlogs, stockouts, and affordability constraints, a long-term, system-wide approach is needed to ensure equitable, reliable access to essential medicines across all levels of care.
This article outlines the key policy levers that, if strategically implemented and adequately resourced, could strengthen South Africa’s health system and create durable improvements in medicine accessibility.
1. Modernising Procurement and Payment Mechanisms
Centralised procurement through the National Department of Health has delivered price advantages in the public sector, particularly for high-burden diseases. However, the system remains vulnerable to delays, supplier disengagement, and irregular payment cycles. As noted in earlier articles, inconsistent payment to suppliers undermines trust and continuity, especially among smaller vendors.
Policy interventions should prioritise:
- The introduction of real-time payment tracking systems,
- Improved contract performance enforcement,
- Incentives for early delivery and penalties for non-performance.
Clear timelines for tender processes, predictable reimbursement, and enhanced financial governance can foster a more stable procurement environment and attract broader supplier participation.
2. Strengthening Regulatory Capacity and Reliance Pathways
The efforts of SAHPRA to clear its inherited backlog and implement reliance models represent important progress. Still, the agency requires expanded capacity, both human and technological, to accelerate the registration of essential medicines and biosimilars.
Key policy actions include:
- Dedicated funding for regulatory digitisation and staffing,
- Fast-tracking of medicines listed on WHO’s Essential Medicines List or approved by reference authorities,
- Formalising differentiated review tracks for life-saving products.
Embedding efficiency into regulatory operations is vital for ensuring timely market entry of high-priority products.
3. Ensuring Transparent, Equitable Pricing Systems
While the Single Exit Price (SEP) model has contributed to pricing transparency in the private sector, affordability remains a barrier for many consumers. In parallel, the lack of SEP application in the public sector creates a fragmented pricing ecosystem.
Policymakers should consider:
- Revising the logistics fee structure to better reflect cost realities,
- Exploring hybrid pricing models for complex therapies,
- Enhancing transparency in public sector tender pricing and supplier performance data.
Regular review of the SEP model, with stakeholder input, will help it evolve with changing market dynamics.
4. Expanding Data Systems for Demand Forecasting and Supply Chain Visibility
Digital platforms like RxSolution and the Stock Visibility System (SVS) have improved transparency in medicine stock levels. Yet inconsistent adoption and poor system integration limit their effectiveness.
To achieve more accurate demand forecasting and equitable stock distribution, policy support should be directed toward:
- Mandating universal adoption of inventory systems across all provinces,
- Linking forecasting systems to disease burden and demographic trends,
- Enhancing district-level redistribution protocols.
Well-integrated data systems can pre-empt shortages and support responsive supply planning.
5. Investing in Workforce Development and Technical Capacity
A well-functioning health system depends on the competencies of its workforce. From pharmacists to regulatory reviewers, training and retention are critical for operational continuity.
Strategic interventions should include:
- Expanded training programs in regulatory science, logistics, and procurement,
- Career development pathways for pharmacists in rural and underserved areas,
- Partnerships with academic institutions for skill-building initiatives.
Addressing human resource gaps is not only a matter of efficiency but also of equity.
Looking Ahead
Policy levers are not isolated instruments, they work best when aligned, sequenced, and supported by political will, cross-sector collaboration, and community engagement. Long-term access to medicines will depend on South Africa’s ability to transform these levers into system-level improvements that are measurable, inclusive, and sustainable.
This article concludes the analytical portion of our series and sets the stage for next month’s concluding theme: Vision and Action — Building a Resilient, Inclusive Pharmaceutical Future. There, we will explore bold, integrated solutions that can future-proof medicine access and ensure health system credibility for generations to come.